NCT01965106View on ClinicalTrials.gov

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
DRUG

QPI-1007 Injection

1.5 mg QPI-1007 Injection

DRUG

(including placebo)

Sham injection procedure

Trial Locations (8)

77030

Robert Cizik Eye Clinic - Clinical Trials Unit, Houston

91105

Doheny Eye Center, UCLA, Pasadena

92868

The Gavin Herbert Eye Institute, UC Irvine, Orange

98104

Dept. of Ophthalmology, University of Washington Medical Center, Seattle

168751

Singapore National Eye Centre, Singapore

Unknown

Hanoi Eye Hospital, Hà Nội

Vietnam National Institute of Ophthalmology, Hà Nội

Ho Chi Minh City Eye Hospital, Ho Chi Minh City

Sponsors
All Listed Sponsors
lead

Quark Pharmaceuticals

INDUSTRY